CSS
DMK

Cubist Systematic Strategies’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Cubist Systematic Strategies’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,655
Closed -$32.9K – 4140
2023
Q2 		$32.9K Buy
+13,655
New +$58.3K ﹤0.01% 3143

Other funds holding DMK

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cubist Systematic Strategies's DMK Position: Q3 2023 in Review

Cubist Systematic Strategies sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q3 2023, closing a stake of 13,655 shares — an estimated $32.9K sold.

Cubist Systematic Strategies first reported a position in DMK in Q2 2023 and held it in 1 quarter. The position peaked at $32.9K in Q2 2023. 25 funds tracked by Wall St. Rank hold DMK as of Q3 2023.

  • Cubist Systematic Strategies reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q3 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 13,655 DMK Pharmaceuticals Corporation Common Stock shares in Q3 2023, an estimated $32.9K.
  • Cubist Systematic Strategies first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q2 2023 and held it in 1 quarter.
  • Cubist Systematic Strategies's DMK Pharmaceuticals Corporation Common Stock position peaked at $32.9K in Q2 2023.
  • 25 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q3 2023.

Based on Cubist Systematic Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.